Related Experiment Video
Updated: Aug 23, 2025

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
Opioid MOP receptor agonists in late-stage development for the treatment of postoperative pain
Qiu Qiu1, Joshua Cj Chew1,2, Michael G Irwin2
1Department of Anaesthesiology, Queen Mary Hospital, Hong Kong, Special Administrative Region, Hong Kong, Kwai Tsing, China.
Introduction:
Opioids remain important in postoperative analgesia although, the focus is on using them as part of multimodal regimens where it is not possible to avoid their use completely. The development of novel agents with more favorable adverse effect profiles may increase safety whilst maintaining efficacy.
Areas Covered:
This article reviews the clinical trials for opioids in late-stage development. The objective of this narrative review is to evaluate the pharmacokinetic properties, safety, tolerability, and analgesic efficacy of these agents in the management of postoperative pain.
Expert Opinion:
Oliceridine appears to be an effective and potentially safer μ opioid receptor agonist. Its main advantages are a relatively fast onset with reduced respiratory depression, nausea, and vomiting. Cebranopadol is an agonist at multiple opioid receptors, of which μ opioid and nociceptin/orphanin FQ peptide (NOP) receptor are most significant. It is an oral drug that appears to have efficacy in neuropathic pain, with reduced respiratory depression and abuse potential. Lastly, morphine-6-glucuronide is an active metabolite of morphine with a slower onset than its parent compound. It has failed to demonstrate appreciable benefit in the context of postoperative analgesia.
Insights
Novel opioids show promise for postoperative pain management, offering improved safety and efficacy. While oliceridine and cebranopadol present potential benefits, morphine-6-glucuronide has not demonstrated significant advantages.
Area of Science:
- Pharmacology
- Pain Management
- Drug Development
Background:
- Opioids are crucial for postoperative analgesia, often used in multimodal approaches.
- Development focuses on novel agents with improved safety and efficacy profiles.
Approach:
- This review evaluates late-stage clinical trials of new opioid analgesics.
- Pharmacokinetic properties, safety, tolerability, and efficacy for postoperative pain were assessed.
Key Points:
- Oliceridine: A μ opioid receptor agonist with rapid onset and reduced adverse effects like respiratory depression and nausea.
- Cebranopadol: A multi-acting receptor-targeted opioid (μ-opioid and NOP receptors) with potential for neuropathic pain and reduced abuse liability.
- Morphine-6-glucuronide: An active metabolite of morphine showing limited benefit in postoperative pain.
Conclusions:
- Oliceridine and cebranopadol represent promising advancements in opioid-based pain management.
- Further research is needed to fully establish the clinical utility of these novel agents.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Receptors: Overview
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

